3.55MMarket Cap-45P/E (TTM)
0.3400High0.2990Low505.45KVolume0.2990Open0.2985Pre Close158.19KTurnover5.50%Turnover RatioLossP/E (Static)10.54MShares7.740052wk High-13.46P/B3.09MFloat Cap0.290152wk Low--Dividend TTM9.20MShs Float59999.9700Historical High--Div YieldTTM13.74%Amplitude0.2901Historical Low0.3120Avg Price1Lot Size
Oragenics Stock Forum
Oragenics Inc. Successfully Completes Key FDA-Recognized Study for ONP-002
Oragenics Inc. (NYSE American: OGEN) has successfully completed a key FDA-recognized study for its concussion drug, ONP-002. The study demonstrated that the intranasal delivery of ONP-002 effectively targets areas in the nose connected to the brain, increasing the likelihood of rapid brain treatment post-concussion. This achievement paves the way for Oragenics to proceed with Phase II human testin...
Oragenics, Inc. Announces Closing of Public Offering
Oragenics, Inc. Provides Update on its Drug Intended to Treat Concussion and Non-Compliance with NYSE American Continued Listing Standards
Oragenics (NYSE American: OGEN) has provided an update on its drug ONP-002, intended to treat concussion, and its non-compliance with NYSE American continued listing standards. Key developments include:
1. Demonstrated stability of ONP-002 across a wide temperature range.
2. Preparation for Phase 2 clinical trials, expected to start i...
Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range
Oragenics Inc. (NYSE American: OGEN) has announced that its lead candidate for treating concussion, ONP-002, demonstrates stability across a wide temperature range (-20°C to 104°C). This eliminates the need for cold storage, making it suitable for field use in sports and military operations. Key points:
1. ONP-002 is a new chemical entitydesigned for in...
No comment yet